{"contentid": 488647, "importid": NaN, "name": "Sanofi-GSK jab set to move into Phase III trial", "introduction": "A Phase II study of the coronavirus vaccine under development by Sanofi (Euronext: SAN) and GlaxoSmithKline (LSE: GSK) has shown the jab achieved strong rates of neutralizing antibody responses.", "content": "<p>A Phase II study of the coronavirus vaccine under development by Sanofi (Euronext: SAN) and GlaxoSmithKline (LSE: GSK) has shown the jab achieved strong rates of neutralizing antibody responses.</p>\n<p>In a statement, Sanofi said the results were in line with those measured in people who have recovered from COVID-19, in all adult age groups.</p>\n<p>The firms have been working together on the adjuvanted recombinant vaccine candidate since early in the pandemic, although progress has been slower than had been hoped.</p>\n<p>In December 2020, a month in which rival vaccine developers such as Pfizer (NYSE: PFE) and AstraZeneca (LSE: AZN) secured first approvals for their options, GSK and Sanofi reported a lower immune response than hoped for in an early trial.</p>\n<p>The latest round of data come from a Phase II study with 720 volunteers, initiated in February, and will pave the way for a Phase III trial to begin in the coming weeks.</p>\n<p>The registrational study is expected to enroll more than 35,000 adult participants from a broad range of countries.</p>\n<p>In parallel, Sanofi has commenced development work against new variants, which will be used to inform next stages of the development program.</p>\n<h2>Interim data</h2>\n<p>The Phase II interim results showed 95% to 100% seroconversion following a second injection in all age groups and across all doses, with acceptable tolerability and with no safety concerns.</p>\n<p>Global head of Sanofi Pasteur Thomas Triomphe said: &ldquo;Our Phase II data confirm the potential of this vaccine to play a role in addressing this ongoing global public health crisis, as we know multiple vaccines will be needed, especially as variants continue to emerge and the need for effective and booster vaccines, which can be stored at normal temperatures, increases.&rdquo;<br /><br />He added: &ldquo;With these favorable results, we are set to progress to a global Phase 3 efficacy study. We look forward to generating additional data and working with our partners around the world to make our vaccine available as quickly as possible.&rdquo;</p>\n<p>Pending positive Phase III outcomes and regulatory reviews, the vaccine is expected to be approved in the fourth quarter of 2021.</p>", "date": "2021-05-17 10:48:00", "meta_title": NaN, "meta_keywords": "Phase, vaccine, Sanofi, study, development, trial, data, Sanofi-GSK, move, rates, responses, antibody, neutralizing, shown, strong, achieved, Euronext, NYS", "meta_description": "A Phase II study of the coronavirus vaccine under development by Sanofi (Euronext: SAN) and GlaxoSmithKline (LSE: GSK) has shown the jab achieved strong rates o", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-17 10:48:36", "updated": "2021-05-17 10:53:08", "access": NaN, "url": "https://www.thepharmaletter.com/article/sanofi-gsk-jab-set-to-move-into-phase-iii-trial", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "covid_big.jpg", "image2id": "covid_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Infectious diseases, Vaccines", "topic_tag": "Coronavirus, Drug Trial, Focus On, Research", "geography_tag": "France, UK", "company_tag": "GlaxoSmithKline, Sanofi", "drug_tag": "VAT00002", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-17 10:48:00"}